RT Journal Article
T1 Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain.
A1 Olry-de-Labry-Lima, Antonio
A1 Špacirova, Zuzana
A1 Fenix-Caballero, Silvia
A1 Hoces, Antonio Matas
A1 Vegas, Adrian Sanchez
A1 Aranzana, Manuel Cárdenas
A1 Sierra-Sanchez, Jesus F
A1 Diaz, Maria Del Carmen Martinez
A1 Alegre Del Rey, Emilio Jesus
K1 Breast neoplasms
K1 Cost-utility analysis
K1 Healthcare costs
K1 Poly(ADP-Ribose) polymerase inhibitors
K1 Progression-free survival
K1 Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
AB Breast cancer is one of the most frequent malignancies. The aim of the article is to analyse the cost-utility ratio and budgetary impact of talazoparib treatment for patients with locally advanced or metastatic gBRCA + breast cancer from the perspective of the Spanish National Health System. Analyses were based on the EMBRACA clinical trial and the model was constructed according to "partitioned survival analysis". Two scenarios were considered in order to compare talazoparib with the alternatives of capecitabine, vinorelbine and eribulin: 1. Chemotherapy in patients pre-treated with anthracyclines/taxanes and, 2. A second- and subsequent-line treatment option. Treatment types following relapse were recorded in the mentioned clinical trial. The effectiveness measure used was quality-adjusted life years (QALY). The average health cost of patients treated at 43 months with talazoparib was 84,360.86€, whilst current treatment costs were 26,683.90€. The effectiveness of talazoparib was 1.93 years of survival (1.09 QALY) relative to 1.58 years (0.83 QALY) in the treatment group. The incremental cost-utility ratio was 252,420.04€/QALY. This represents the additional cost required to earn an additional QALY when changing from regular treatment to talazoparib. Regarding budgetary impact, the number of patients susceptible to receiving treatment with between 94 and 202 talazoparib was estimated, according to scenario and likelihood. The 3-year cost difference was between 6.9 and 9 million euros. The economic evaluation conducted shows an elevated incremental cost-utility ratio and budgetary impact. Taking these results into account, the price of talazoparib would have to be lower than that taken as a reference to reach the cost-utility thresholds.
PB Elsevier
YR 2021
FD 2021-04-12
LK http://hdl.handle.net/10668/17627
UL http://hdl.handle.net/10668/17627
LA en
NO Olry de Labry Lima A, Špacírová Z, Fénix-Caballero S, Hoces AM, Vegas AS, Aranzana MC, et al. Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain. Breast. 2021 Aug;58:27-33
DS RISalud
RD Apr 17, 2025